Sarcoma-specific CAR-T cells

PreclinicalCell therapy

SShenzhen Geno-Immune Medical Institute

Sarcoma-specific CAR-T cells is one of 17 biologic programs targeting Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SarcomaNot yet recruiting

SarcomaPreclinical

Not yet recruiting

Competition

Competitive Landscape

17 competitors in Sarcoma

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

2 2

Keytruda

Merck & Co.

Phase 2

2 3

Tecentriq

Roche

Phase 2

1 4

Amtagvi

IIovance Biotherapeutics, Inc.

Phase 2

1 5

IC-Green

PProvepharm SAS

Phase 2

1 6

Talimogene Laherparepvec

Amgen

Phase 2

3 7

Biological

NNational Environment Agency, Singapore

Phase 1

1 8

NKTR-214

Bristol-Myers Squibb

Phase 2

1 9

Rapamune

PPrism Pharmaceuticals

Preclinical

1 10

NEULASTA

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalNot yet recruiting

Sarcoma

NCT03356782

Clinical

Trials by Indication[1]

Sarcoma1 trial

Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas

Not yet recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03356782·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sarcoma-specific CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sarcoma-specific CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sarcoma-specific CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: SShenzhen Geno-Immune Medical Institute

Sarcoma-specific CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Sarcoma1 trial

References

Drug Info

Quick Facts

Related News